Press release

MedCision to co-host Breakfast Session with TrakCel and Present Poster at ISCT 2017

The Cost of No Automation and Standardization in Cell Therapy

SAN RAFAEL, Calif. – April 25, 2017 – MedCision, LLC, world leader in the automation of pre-clinical and clinical cell thawing, today announced the company’s participation in the 2017 International Society for Cellular Therapy (ISCT) Annual Meeting. This event will discuss and generate solutions to challenges throughout the cell therapy industry, from preclinical to translational development, to delivery of therapies for patients. MedCision will co-host a breakfast session with partner TrakCel, present a scientific poster, and exhibit its latest technologies for vital clinical cell thawing.

MedCision’s Chief Commercial Officer, Samuel Kent, and TrakCel’s Chief Scientific Officer, Matthew Lakelin, will present on “Automating Downstream Processes in Cell Therapy: How Innovative Point-Of-Care Solutions Ensure Consistency and Traceability in a Complex Supply Chain.” This breakfast tutorial will be held Thursday, May 4 from 7:30-8:30 a.m. in the Platinum 4 Room at the ExCeL London meeting venue.

“The importance of automation and standardization of the thawing process for cell therapies remains under-appreciated for frozen cell therapeutics,” said Lakelin. “TrakCel and MedCision share a common goal to bring reproducibility and reliability into the cell therapy process.”

Also on May 4, from 5:30-6:30 p.m., the company’s Marketing and Sales Specialist, Lily Thompson, will lead a poster session titled, “Process Automation Helps Standardize and De-Risk Thawing of Cellular Therapy Products.”  

 “Cell thawing, the last step a cellular drug product undergoes before doctors can administer it to patients, is the most important part of the post-manufacturing process,” said Samuel Kent and CCO of MedCision. “At ISCT, we will provide new insights into the role automation plays in avoiding human error and ensuring predictable patient outcomes.”

About MedCision
MedCision develops automation technologies for vital clinical product handling processes.  An industry first, the ThawSTAR Automated Cell Thawing System replaces uncontrolled and highly variable manual methods with a customizable algorithm to thaw each unique cell therapy product to maintain maximum cellular efficacy. MedCision’s global customers include pharmaceutical, medical, stem cell and other GMP facilities where consistent and repeatable outcomes are paramount.

For more information please visit www.medcision.com or www.medcision.com/blog/.

About TrakCel

TrakCel's cell, gene and immunotherapy management solution improves clinical study efficacy and accelerates global scale-up and scale-out by implementing communications technology to integrate the delivery path from needle-to-needle. The technology provides interactive instructions to
professionals across the supply chain and gives stakeholders on-demand visibility of procedural results and chain-of-custody data for immediate traceability, validation and compliance audits. 

TrakCel technology is increasingly being adopted by leaders in the cell, gene and immunotherapy industry. TrakCel is headquartered in Cardiff, Wales with a U.S. offices in Newport Beach, California  and Bridgewater, NJ.

For more information please visit www.trakcel.com.

Medcision Media contact information:
Marla Kertzman
mkertzman@medcision.com
209 852 9027

EAP contact:
Samuel Kent
busdev@medcision.
415 342 481


TrakCel Media & Investor Relations
Hannah James
Marketing manager
TrakCel Ltd.
pr@trackcel.com